1)Watari H, et al : Phase III trial to confirm the superiority of pelvic and para-aortic lymphadenectomy to pelvic lymphadenectomy alone for endometrial cancer : Japan Clinical Oncology Group study 1412(SEPAL-P3). Jpn J Clin Oncol 47 : 986-990, 2017
2)Benedetti Panici P, et al : Systematic pelvic lymphadenectomy vs no lymphadenectomy in early stage endometrial carcinoma : rando- mized clinical trial. J Natl Cancer Inst 100 : 1707-1716, 2008
3)Kitchener H, et al : Efficacy of systematic pelvic lymphadenectomy in endometrial cancer(MRC ASTEC trial): a randomised study. Lancet 373 : 125-136, 2009
4)Todo Y, et al : Survival effect of para-aortic lymphadenectomy in endometrial can- cer(SEPAL study): a retrospective cohort analysis. Lancet 375 : 1165-1172, 2010
5)Susumu N, et al : Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer. a Japanese Gynecologic Oncology Group study. Gynecol Oncol 108 : 228-233, 2008
6)Randall ME, et al : Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma : a Gynecologic Oncology Group Study. J Clin Oncol 24 : 36-44, 2006
7)Watanabe Y, et al : Practice pattern for postoperative management of endometrial cancer in Japan : a survey of the Japanese Gynecologic Oncology Group. Gynecol Oncol 115 : 456-459, 2009
8)Miller D, et al : Randomized phase III noninferiority trial of first-line chemotherapy for metastatic or recurrent endometrial carcinoma : a Gynecologic Oncology Group study. Gynecol Oncol 125 : 771-773, 2012
9)Nomura H, et al : Effect of taxane plus platinum regimens vs doxorubicin plus cisplatin as adjuvant chemotherapy for endometrial cancer at a high risk of progression : a randomized clinical trial. JAMA Oncol 5 : 833-840, 2019